Incorrect password
evipedia.ai Suggest Edit

NAD+ for Health & Longevity

Evidence Review created on 04/26/2026 using AI4L / Opus 4.7

Also known as: Nicotinamide Adenine Dinucleotide, NAD, Coenzyme 1

Motivation

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It powers fundamental processes: producing cellular energy, repairing damaged DNA, regulating metabolism, and supporting a family of enzymes linked to longevity. Levels of NAD+ decline substantially with age, and that decline has been implicated in many of the conditions that come with growing older, from metabolic dysfunction to neurodegeneration.

Restoring NAD+ has become one of the most actively investigated longevity strategies of the past decade. Because NAD+ itself does not cross cell membranes well when taken by mouth, most strategies rely on precursors such as nicotinamide riboside, nicotinamide mononucleotide, niacin, and nicotinamide. Early animal data sparked enormous enthusiasm, and a growing body of human trials has confirmed that blood NAD+ levels can be raised, although translation to disease-relevant outcomes has been mixed.

This review examines the current human evidence on NAD+ restoration, weighing demonstrated effects against open questions, mechanistic plausibility, and practical considerations relevant to longevity-oriented adults.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality resources providing a broad overview of NAD+ biology and the rationale for raising NAD+ levels in the context of healthy aging.

Grokipedia

Nicotinamide Adenine Dinucleotide

A reference article covering NAD+’s biochemistry, redox role, the de novo and salvage biosynthetic pathways, and its place in cellular metabolism, providing useful background context for understanding why NAD+ restoration is being pursued therapeutically.

Examine

No dedicated Examine.com article exists for NAD+ as a stand-alone intervention. Examine maintains separate supplement pages for individual NAD+ precursors (NMN, niacin) and an outcome page on serum NAD+ levels, but no primary page for NAD+ itself.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, NMN)

An independent product testing review evaluating NAD+, NADH, nicotinamide riboside, and NMN supplements for actual ingredient content, contamination, and price, revealing wide quality variation across brands and identifying top picks based on third-party laboratory testing.

Systematic Reviews

A selection of systematic reviews and meta-analyses examining the human evidence for raising NAD+ via supplementation.

Mechanism of Action

NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme present in every cell. It exists in two interconverting forms — NAD+ (oxidized) and NADH (reduced) — and serves both as a hydride carrier in energy metabolism and as a substrate consumed by a family of NAD+-dependent enzymes that include sirtuins, PARPs (poly-ADP-ribose polymerases, enzymes that repair DNA damage), and CD38 (a NAD+-consuming enzyme involved in immune signaling whose expression rises with age).

Cellular NAD+ is maintained by three pathways:

  • De novo pathway: Tryptophan is converted through the kynurenine pathway via QPRT (quinolinate phosphoribosyltransferase, the final enzyme producing NAMN — nicotinic acid mononucleotide) to NAD+
  • Preiss-Handler pathway: Niacin (nicotinic acid) is converted to NAMN, then to NAAD (nicotinic acid adenine dinucleotide), then to NAD+
  • Salvage pathway: Nicotinamide is converted to NMN by NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme), and NMN is converted to NAD+ by NMNAT enzymes (nicotinamide mononucleotide adenylyltransferases). Nicotinamide riboside enters this pathway via NRK1/2 (nicotinamide riboside kinases)

Because intact NAD+ does not efficiently cross cell membranes when taken by mouth, oral NAD+ supplementation relies on precursors. Recent human research (Christen et al., 2026; Nature Metabolism) clarified that NR and NMN raise circulating NAD+ comparably over 14 days, while orally administered nicotinamide does not durably elevate NAD+. The same study demonstrated that NR and NMN are partly converted by gut microbiota to nicotinic acid (NA), which then enters the Preiss-Handler pathway — challenging the simpler “NMN-direct-uptake” model that had dominated the field. A competing mechanistic camp continues to argue that intact NMN can be transported directly via the SLC12A8 transporter (a membrane protein proposed to import intact NMN into cells); both views remain actively debated.

By replenishing NAD+, supplementation supports several longevity-associated processes:

  • Sirtuins (SIRT1-7, NAD+-dependent deacetylases involved in DNA repair, metabolic regulation, and stress resistance): NAD+ is a required co-substrate; declining NAD+ with age reduces sirtuin activity
  • PARPs: PARPs consume NAD+ to repair DNA strand breaks; adequate NAD+ supply supports genomic integrity
  • CD38: A major driver of age-related NAD+ decline; NAD+ supplementation helps offset CD38-driven depletion
  • Mitochondrial function: NAD+/NADH cycling is essential for oxidative phosphorylation and ATP (adenosine triphosphate, the cell’s energy currency) production

Key pharmacological properties (oral NAD+ precursors):

  • Half-life: NR and NMN are rapidly cleared from plasma (peaks within 30–60 minutes), but the resulting whole-blood NAD+ elevation persists for approximately 8–24 hours
  • Selectivity: Substrates for NAD+ biosynthetic enzymes; not receptor ligands
  • Tissue distribution: NAD+ elevation is most consistently observed in blood; preclinical evidence supports liver, muscle, and kidney uptake. Brain penetration in humans remains debated and likely depends on the precursor
  • Metabolism: Primarily through the salvage and Preiss-Handler pathways; nicotinamide is the major terminal metabolite, excreted via the kidneys

Historical Context & Evolution

NAD was discovered in 1906 by Sir Arthur Harden and William John Young as a “coferment” required for fermentation in yeast. Otto Warburg later showed it functioned as a hydride acceptor in cellular respiration. For most of the 20th century, NAD+ was treated as a textbook redox cofactor — important but stable, abundant, and not therapeutically interesting. Niacin (nicotinic acid), recognized as the cure for pellagra in the 1930s, became the first NAD+-raising therapy.

Interest in NAD+ as a longevity intervention emerged in the 2000s when Leonard Guarente’s laboratory at MIT demonstrated that sirtuins required NAD+ as a substrate. David Sinclair’s work, building on this, proposed that age-related NAD+ decline drove sirtuin dysfunction and contributed to many hallmarks of aging. Charles Brenner’s 2004 discovery of nicotinamide riboside as a natural NAD+ precursor opened a practical supplementation route. NMN entered the picture more prominently after 2013, with Sinclair-laboratory mouse studies showing NMN reversed aspects of mitochondrial aging.

The first human safety trials of NR appeared in 2016–2018, NMN trials in 2019–2022, and the human evidence base has expanded rapidly since. Findings have produced a more measured picture than early animal work suggested: blood NAD+ elevation is consistently confirmed across precursors, but disease-relevant outcomes have been mixed and frequently null on pooled analysis. The field remains in flux, with active debate over which precursor is most effective, whether intracellular tissue NAD+ is actually raised in target organs, and how much of the NAD+-boosting effect of oral NR and NMN is mediated by gut-microbial conversion to nicotinic acid (Christen et al., 2026).

Expected Benefits

A dedicated search for the benefit profile of NAD+ restoration was performed using PubMed, clinical trial databases, expert sources, Examine.com, and ConsumerLab before writing this section. Conflict of interest note: A meaningful share of the NAD+ literature — including ingredient-validation studies, brand-funded clinical trials, and trade-association communications — originates from parties with a direct financial interest in NAD+ supplementation’s adoption (ingredient suppliers such as ChromaDex/NIAGEN®, Uthever®/Effepharm, finished-product manufacturers, IV-clinic networks, and dietary-supplement industry advocacy groups). The benefit claims below should be read in that context.

High 🟩 🟩 🟩

Restoration of Blood NAD+ Levels

Multiple RCTs and meta-analyses have consistently demonstrated that oral NR (250–1,000 mg/day) and NMN (250–900 mg/day) significantly increase whole-blood NAD+ within 2–4 weeks. The Norheim et al. (2024) Nature Aging trial reported a more-than-twofold increase in whole-blood NAD+ with 6 weeks of NR. The Christen et al. (2026) Nature Metabolism head-to-head trial confirmed that NR and NMN raise circulating NAD+ comparably over 14 days, while oral nicotinamide does not durably elevate NAD+. Niacin (nicotinic acid) is also well established to raise NAD+ via the Preiss-Handler pathway.

Magnitude: Whole-blood NAD+ increases of approximately 50–150% over baseline, depending on precursor, dose, and duration.

Improved Lipid Profile (with niacin / NAD+ precursors at higher doses)

The Zhong et al. (2022) meta-analysis of 40 trials (n=14,750) and the Oliveira-Cruz et al. (2024) meta-analysis of 19 trials show that NAD+ precursor supplementation as a class — most strongly niacin — significantly reduces triglycerides, total cholesterol, and LDL, and raises HDL, with the largest effects in adults with cardiovascular disease or dyslipidemia. This benefit is well established for niacin and is the basis for niacin’s approved use in dyslipidemia.

Magnitude: Standardized mean difference (SMD, a unitless measure expressing effect size in standard deviations) of approximately -0.33 to -0.38 for total cholesterol and LDL; +0.66 for HDL across pooled trials.

Medium 🟩 🟩

Reduced Airway and Systemic Inflammation

The Norheim et al. (2024) Nature Aging RCT in patients with chronic obstructive pulmonary disease (COPD) found that 6 weeks of NR supplementation reduced sputum IL-8 (interleukin-8, a pro-inflammatory cytokine) by approximately 53% versus placebo, with effects persisting 12 weeks after discontinuation. Exploratory analyses pointed to reduced epigenetic aging and signs of decreased cellular senescence. Other trials have shown NAD+ precursors reduce hs-CRP (high-sensitivity C-reactive protein, a marker of systemic inflammation) and IL-6 (interleukin-6, another inflammatory cytokine), with inconsistent magnitude.

Magnitude: Approximately 53% reduction in airway IL-8 in the COPD trial; effects on systemic CRP/IL-6 are smaller and less consistent.

Reduced Arterial Stiffness and Systolic Blood Pressure

Pilot data from Martens et al. (2018) showed 6 weeks of NR (500 mg twice daily) reduced systolic blood pressure by approximately 8 mmHg in adults with elevated baseline blood pressure and reduced aortic stiffness. The ongoing Phase 2 NCT03821623 trial is testing this in a larger cohort. The Shoji et al. (2025) RCT in Werner syndrome (a progeroid syndrome with accelerated NAD+ decline) demonstrated improved cardio-ankle vascular index — a measure of arterial stiffness — after NR.

Magnitude: Approximately 8 mmHg reduction in systolic blood pressure in the Martens pilot; arterial stiffness improvements documented but variably quantified.

Low 🟩

Improved Physical Performance & Endurance ⚠️ Conflicted

Some RCTs (e.g., the Yi et al. 2023 NMN trial) have shown improvements in six-minute walking distance and aerobic capacity in middle-aged and older adults, while the Prokopidis et al. (2025) meta-analysis of NMN and NR found no significant pooled effect on skeletal muscle index, handgrip strength, gait speed, or chair-stand performance in adults with mean age over 60. The discrepancy may reflect smaller individual trials reporting positive findings while pooled analysis reverts to null, or genuine heterogeneity by population (NR was associated with longer 6-minute walk distance specifically in peripheral artery disease subjects).

Magnitude: Approximately 30–55 meter improvement in six-minute walking distance in positive single trials; no significant effect on most muscle outcomes in pooled meta-analysis.

Improved Insulin Sensitivity ⚠️ Conflicted

The Yoshino et al. (2021) trial in overweight, prediabetic postmenopausal women found that NMN (250 mg/day for 10 weeks) improved muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. Subsequent NMN meta-analyses (Chen et al. 2024; Zhang et al. 2025) found no significant pooled effects on fasting glucose, fasting insulin, HbA1c (glycated hemoglobin, a marker of long-term blood sugar control), or HOMA-IR (homeostatic model assessment of insulin resistance). The Zhong et al. (2022) meta-analysis observed that NAD+ precursors as a class — driven by niacin — actually raised fasting glucose. Discrepancies likely reflect differences in precursor type, measurement method, and population.

Magnitude: Approximately 25% improvement in muscle insulin sensitivity in the Yoshino trial; pooled meta-analyses show no benefit on standard glycemic markers and a small adverse effect from niacin.

Improved Sleep Quality

The Morifuji et al. (2024) NMN RCT in older adults found improved subjective sleep quality and reduced daytime sleepiness; the Kim et al. (2022) NMN trial reported reductions in sleep-related fatigue.

Magnitude: Statistically significant improvement in Pittsburgh Sleep Quality Index scores versus placebo; effect size modest.

Improved Vascular and Cognitive Function in Specific Populations

The Szarvas et al. (2025) pilot trial in patients with peripheral artery disease found 4 weeks of NR was associated with improved cerebrovascular response and cognitive performance across multiple domains, alongside reduced oxidative stress. The Shoji et al. (2025) crossover RCT in Werner syndrome demonstrated improved arterial stiffness, smaller skin ulcer area, and apparent renal function preservation.

Magnitude: Not quantified in available studies.

Speculative 🟨

Slowed Biological Aging

Some NMN and NR trials have observed reduced epigenetic age (DNA methylation-based clocks) and signs of decreased cellular senescence (Yi et al. 2023; Norheim et al. 2024). These remain preliminary signals requiring confirmation in larger trials with multiple, validated epigenetic clocks before being considered established.

Neuroprotection

Preclinical work consistently shows NAD+ precursors protect neurons in models of Alzheimer’s disease, Parkinson’s disease, and glaucoma (Alghamdi & Braidy, 2024). Human cognitive endpoints have not been demonstrated outside small pilots; the NEAT trial (Ketron et al., 2025) examined nicotinamide pharmacokinetics in early Alzheimer’s. A Phase 2 glaucoma trial (NCT06991712) is testing NAD+ precursors for neuroprotection.

Reproductive Aging

Animal data show NAD+ precursors rescue oocyte quality and female fertility decline in mice. Human RCTs (NCT06426355) are recruiting in diminished ovarian reserve. Without controlled human results, this remains a mechanistic and animal-model signal only.

Lifespan Extension

While NAD+ precursors extend lifespan in mice, no human trial has been designed or powered to test lifespan extension. Surrogate longevity outcomes (functional capacity, biological-age clocks) are being collected, but a confirmed lifespan effect in humans is not established.

Benefit-Modifying Factors

  • Baseline NAD+ levels: Individuals with lower baseline NAD+ — typically older adults, those with metabolic dysfunction, or those with progeroid conditions like Werner syndrome — may experience greater benefits from supplementation. Younger adults with adequate baseline NAD+ likely see smaller responses.

  • Age: NAD+ decline accelerates after age 40; most clinical trials enrolled adults aged 45+, and benefits appear more pronounced in this age range.

  • Sex-based differences: The Yoshino et al. (2021) NMN insulin-sensitivity trial enrolled only postmenopausal women; whether comparable metabolic benefits occur in men is not established. Sex differences in NAD+ metabolism have been documented preclinically but are poorly characterized in humans.

  • Pre-existing health status: Adults with cardiovascular disease, dyslipidemia, prediabetes, or COPD are more likely to show measurable benefits than metabolically healthy individuals (Zhong et al. 2022; Norheim et al. 2024). The benefit signal in healthy younger adults is weaker.

  • Genetic polymorphisms: Variants in NAMPT (the rate-limiting enzyme of NAD+ salvage), CD38 (the major NAD+-degrading enzyme whose activity rises with age), SIRT1, and PARP1 (poly-ADP-ribose polymerase 1, a major NAD+-consuming DNA repair enzyme) may modulate response, though direct genotype-stratified data in supplementation trials are limited.

  • Choice of precursor: NR and NMN raise circulating NAD+ comparably; nicotinic acid (niacin) is the most effective for lipid outcomes; oral nicotinamide does not durably raise NAD+ (Christen et al. 2026). Outcome priorities should drive precursor choice.

  • Gut microbiome: Recent human work (Christen et al. 2026) suggests that gut-microbial conversion of NR and NMN to nicotinic acid contributes substantially to their NAD+-boosting effect, implying that microbiome composition may modify response.

Potential Risks & Side Effects

A dedicated search for the side effect profile of NAD+ restoration was performed using PubMed, Examine.com, drugs.com, prescribing information for niacin, clinical trial safety data, and expert sources before writing this section.

High 🟥 🟥 🟥

Niacin Flushing (Nicotinic Acid Specific)

Immediate-release niacin at doses above 50–100 mg routinely causes prostaglandin-mediated cutaneous flushing — warmth, redness, itching, and tingling — typically within 15–30 minutes of dosing and lasting 1–2 hours. This is the single most common adverse effect of any NAD+-raising therapy. NR and NMN cause far less flushing than niacin at NAD+-equivalent doses.

Magnitude: Affects the majority of niacin users at therapeutic doses, especially with immediate-release formulations; tolerance often develops with continued use.

Mild Gastrointestinal Symptoms

Across NR and NMN clinical trials, the most commonly reported adverse events are mild gastrointestinal complaints including nausea, bloating, diarrhea, and abdominal discomfort. The Fukamizu et al. (2022) and multiple NR safety trials confirmed good tolerability at doses up to 1,000–1,200 mg/day, with no serious treatment-related events.

Magnitude: Incidence rates are typically comparable to placebo in modern trials of NR/NMN; symptoms are generally mild and self-limiting.

Medium 🟥 🟥

Hepatotoxicity (Niacin Specific)

Sustained-release niacin formulations have a well-documented risk of hepatotoxicity, including transaminase elevations and rare cases of fulminant hepatic failure. This risk is much lower with immediate-release niacin and has not been observed at meaningful rates in NR or NMN trials. The Gindri et al. (2024) systematic review of NAD/NADH supplementation reported the spectrum of liver-related adverse events.

Magnitude: Transaminase elevations occur in approximately 1–5% of patients on therapeutic niacin doses; severe hepatotoxicity is rare but well documented in pharmacovigilance.

Low 🟥

Worsened Glycemic Control (Niacin / High-Dose NAD+ Precursors)

The Zhong et al. (2022) meta-analysis found NAD+ precursors as a class — driven by niacin — significantly raised fasting plasma glucose. Niacin’s adverse glycemic effect is well established. NR and NMN have not consistently shown this signal in their own pooled analyses, but the possibility warrants monitoring in adults with prediabetes or diabetes.

Magnitude: Standardized mean difference of approximately +0.27 for fasting plasma glucose across pooled trials; clinically meaningful for adults with impaired glucose tolerance.

Transient Liver Enzyme Elevation (NR / NMN)

Some clinical trials and pharmacovigilance reports note transient ALT/AST (alanine and aspartate aminotransferase, liver enzymes) elevations with NAD+ precursor use; serious liver injury has not been reported in NR or NMN RCTs to date, but baseline screening and monitoring are appropriate, especially in those with pre-existing liver conditions.

Magnitude: Not quantified in available studies.

Increased Methylation Demand

Nicotinamide is metabolized in the liver via methylation (consuming SAMe — S-adenosylmethionine, the body’s primary methyl donor) to N-methylnicotinamide. High doses of any NAD+ precursor that flux through nicotinamide can theoretically increase methyl-group demand and elevate plasma homocysteine. This is most relevant for high-dose nicotinamide and less so for NR/NMN at standard doses.

Magnitude: Not quantified in available studies.

Headaches, Fatigue, Sleep Disturbance

The Gindri et al. (2024) systematic review noted muscle pain, fatigue, sleep disturbance, and headaches across studies of NAD+/NADH supplementation. These are typically mild and not considered serious risks.

Magnitude: Not quantified in available studies.

Speculative 🟨

Theoretical Cancer Concern

A theoretical concern exists that boosting NAD+ could support the metabolism of pre-existing cancer cells, since cancer cells also rely on NAD+. No clinical evidence supports this concern for NAD+ precursors specifically, but oncologists commonly recommend pausing NAD+ precursors during active cancer treatment, particularly when PARP inhibitors (drugs that exploit NAD+ depletion to kill cancer cells) are in use. NAD+ supports both the genome-stability functions PARPs provide in healthy cells and, theoretically, the survival of cancer cells.

Safety of IV NAD+

Intravenous NAD+ is offered by many longevity clinics but has limited rigorous human safety and efficacy data. Side effects reported include chest pressure, nausea, and abdominal cramping during infusion. Oral precursors are far better characterized; the case for IV NAD+ rests largely on practitioner reports and small case series.

Unknown Long-Term Effects

The longest published RCTs of NR and NMN run 6–12 weeks; the Werner syndrome NR crossover trial extended to 26 weeks per arm. Multi-year safety data in healthy adults remain absent. While short-term data are reassuring, the absence of long-term human data is a real evidentiary gap.

Risk-Modifying Factors

  • Genetic polymorphisms: No specific variants have been confirmed to substantially modify the risk profile of NAD+ precursors in humans. Variants affecting NAMPT, CD38, or methylation-cycle enzymes (e.g., MTHFR — methylenetetrahydrofolate reductase, an enzyme regulating folate and methylation) could theoretically alter risk, particularly for nicotinamide-flux-related methyl-group demand.

  • Baseline biomarker levels: Adults with elevated liver enzymes, impaired kidney function, prediabetes, or elevated homocysteine at baseline may be at greater risk for adverse effects and warrant more frequent monitoring.

  • Sex-based differences: No clinically significant sex-based differences in NAD+ precursor adverse events have been identified; the total number of participants studied remains relatively small.

  • Pre-existing health conditions: Liver disease, kidney disease, gout (niacin can raise uric acid), diabetes (niacin can worsen glycemia), and active cancer increase the relevance of monitoring or avoidance. Adults on PARP inhibitor cancer therapy should not take NAD+ precursors.

  • Age-related considerations: Adults over 65 may have reduced kidney and liver clearance affecting metabolite handling; clinical-trial protocols in this age group typically use lower starting doses and more frequent monitoring.

Key Interactions & Contraindications

Prescription drug interactions:

  • PARP inhibitors (olaparib, niraparib, talazoparib): NAD+ precursor supplementation could counteract the mechanism of PARP inhibitors, which deplete NAD+ in cancer cells. Severity: absolute contraindication during active cancer treatment with these agents. Mitigating action: discontinue NAD+ precursors during PARP-inhibitor therapy.
  • Statins (atorvastatin, rosuvastatin, simvastatin): Concurrent niacin and statins increase the risk of myopathy and rhabdomyolysis (a severe muscle-breakdown condition). Severity: caution. Mitigating action: monitor CK (creatine kinase, a muscle-injury marker) and symptoms; avoid combining high-dose niacin with high-dose statins.
  • Antihypertensives (ACE inhibitors — angiotensin-converting enzyme inhibitors that lower blood pressure — such as lisinopril; ARBs — angiotensin receptor blockers — such as losartan; calcium channel blockers such as amlodipine; alpha-blockers): Niacin causes vasodilation and can produce additive hypotension. NR and NMN have a milder blood-pressure-lowering signal. Severity: caution and monitor. Mitigating action: monitor blood pressure when adding NAD+ precursors.
  • Diabetes medications (insulin, metformin, sulfonylureas such as glipizide, SGLT2 inhibitors — sodium-glucose cotransporter-2 inhibitors that lower blood glucose by promoting urinary glucose excretion — such as empagliflozin): Niacin can worsen glycemic control; NR and NMN have neutral or favorable but inconsistent signals. Severity: caution and monitor. Mitigating action: monitor fasting and postprandial glucose, especially during the first 4–8 weeks; titrate diabetes therapy as needed.
  • Anticoagulants (warfarin, apixaban, rivaroxaban): Niacin may modestly affect platelet function. Severity: caution. Mitigating action: monitor bleeding risk and INR (international normalized ratio, a measure of blood-clotting time) if on warfarin.
  • Thyroid medications (levothyroxine): Anecdotal reports of timing-based interactions with NAD+ precursors. Severity: caution. Mitigating action: separate dosing by at least 2 hours.

Over-the-counter medication interactions:

  • Aspirin: Often used pre-niacin to reduce flushing; not contraindicated, but additive bleeding-risk awareness applies.
  • High-dose niacin (vitamin B3): Adding high-dose niacin to NR or NMN supplementation increases the total NAD+ pathway flux and can amplify flushing and lipid effects. Severity: caution. Mitigating action: avoid stacking high-dose niacin with other NAD+ precursors; consider total cumulative intake.

Supplement interactions:

  • NR + NMN: Feed into the same NAD+ synthesis pathway; effects on NAD+ are additive. Stacking is common but the combined dose should be considered.
  • Resveratrol: Often co-administered based on the hypothesis that NAD+ precursors fuel sirtuins while resveratrol activates SIRT1. Mechanistic synergy is plausible; demonstrated additive benefit in human outcomes is not established.
  • CD38 inhibitors (apigenin, quercetin, luteolin): These flavonoids inhibit CD38 and may enhance NAD+ retention; clinical magnitude has not been established.
  • Methyl donors (TMG — trimethylglycine, also known as betaine; SAMe — S-adenosylmethionine; methylated B-vitamins): Sometimes added to offset the methylation demand of nicotinamide metabolism, particularly in MTHFR variants or with high-dose nicotinamide.
  • Other NAD+ precursors (niacin, nicotinamide): Additive effects on NAD+ pathway activity; consider total cumulative intake.

Populations who should avoid NAD+ supplementation:

  • Pregnant or breastfeeding women (insufficient safety data)
  • Adults with active cancer, particularly on PARP inhibitor therapy (absolute contraindication during PARP-inhibitor regimens)
  • Adults with severe liver disease (Child-Pugh Class B or C — a clinical scoring system for liver disease severity) without physician supervision
  • Adults with advanced chronic kidney disease (CKD — chronic kidney disease; eGFR — estimated glomerular filtration rate <30 mL/min/1.73m², Stage 4 or 5) without physician supervision
  • Adults with active gout or hyperuricemia, regarding niacin specifically
  • Children and adolescents (no safety data in these populations)

Risk Mitigation Strategies

  • Low starting dose with gradual escalation: Start NR or NMN at 250 mg/day for the first 2–4 weeks before escalating to 500–1,000 mg/day. For niacin, start at 100–250 mg with a gradual dose-up over weeks. This mitigates gastrointestinal symptoms, niacin flushing, and allows tolerability assessment.

  • Pre-treat niacin flushing with low-dose aspirin and slow-release formulations: When niacin is the chosen precursor, pre-treat 30 minutes before the dose with 325 mg aspirin (if aspirin-tolerant) and use extended-release or sustained-release niacin under medical supervision. This mitigates the flushing reaction that drives most niacin discontinuation.

  • Baseline and follow-up labs for liver, kidney, and metabolic function: Obtain CMP (comprehensive metabolic panel), lipid panel, fasting glucose/HbA1c, and uric acid before starting NAD+ precursors and repeat at 3 months, then every 6 months — particularly for adults over 60 or with pre-existing conditions. This mitigates hepatotoxicity (especially with niacin), worsened glycemic control, hyperuricemia, and detects transient enzyme elevations.

  • Take with food: Administer NR/NMN/niacin with a meal to reduce gastrointestinal symptoms and, for niacin, to slow absorption and reduce flushing intensity.

  • Discontinue NAD+ precursors prior to PARP-inhibitor cancer therapy: Pause NAD+ supplementation at least 2 weeks ahead of any planned chemotherapy that includes PARP inhibitors, and consult an oncologist before resuming. This addresses the absolute contraindication with PARP inhibitor mechanisms.

  • Choose third-party-tested products: Selection of NR (NIAGEN®), NMN (Uthever®, MIB-626 in research settings), and niacin from brands providing independent certificates of analysis (COA) is a common quality-control approach. Independent ConsumerLab testing has found 29 of 39 NR products and 14 of 22 popular NMN products contained little to no labeled active ingredient. This mitigates the practical risk of receiving an inactive or contaminated product.

  • Add methyl donor support if using high-dose nicotinamide: Consider co-supplementation with TMG, folate, B12, or B6 to support methylation when using high-dose nicotinamide chronically. This mitigates the theoretical methyl-group depletion associated with nicotinamide flux.

  • Avoid IV NAD+ outside controlled settings unless practitioner-supervised: IV NAD+ has limited rigorous data and reported infusion reactions; if used, only under licensed practitioner supervision with appropriate monitoring. Oral precursors are better characterized for routine use.

  • Monitor and report persistent side effects: Track flushing, GI symptoms, fatigue, sleep changes, and unexpected lab results; consider dose reduction or discontinuation if persistent.

Therapeutic Protocol

There is no single “standard” NAD+ protocol. Leading practitioners and researchers offer several distinct approaches reflecting different goals and weights of evidence. David Sinclair, PhD (Harvard Medical School) is widely credited with popularizing NMN supplementation for longevity and has publicly described taking approximately 1,000 mg/day NMN. Charles Brenner, PhD (City of Hope), the discoverer of NR as an NAD+ precursor, has championed NR specifically. Peter Attia, MD has expressed a more cautious stance based on the limited human metabolic outcomes data, taking NR and NMN at lower doses while waiting for stronger evidence. Andrew Huberman, PhD reports personal use of both NR and NMN primarily for energy, not lifespan extension. Functional medicine practice often includes low-dose niacin or nicotinamide for specific cardiovascular or dermatologic indications. These competing approaches all share the goal of raising NAD+, but differ on which precursor and at what dose.

  • NR (nicotinamide riboside) standard dose: 300–1,000 mg/day. ChromaDex’s NIAGEN® brand is the most studied, with Tru Niagen and Life Extension’s NAD+ Cell Regenerator being the most common consumer formulations.

  • NMN (nicotinamide mononucleotide) standard dose: 250–900 mg/day. Uthever® is the most widely tested and validated raw ingredient.

  • Niacin (nicotinic acid) standard dose: 500–2,000 mg/day for lipid-modifying effect, used under medical supervision; doses below 100 mg generally do not produce flushing or lipid effect.

  • Nicotinamide (niacinamide) standard dose: Up to 500–1,000 mg/day for dermatologic indications (e.g., non-melanoma skin cancer prevention, Chen et al. 2015 ONTRAC trial, in which a separate review of nicotinamide is recommended). Christen et al. (2026) found nicotinamide does not durably raise NAD+, so it is not optimal for an NAD+-raising goal.

  • IV NAD+ protocols: 250–1,000 mg infusions over 2–4 hours, typically 1–10 sessions; offered by longevity clinics. Limited rigorous comparative human data.

  • Best time of day: Morning dosing is the standard approach, aligning with circadian NAD+ biology (NAMPT expression peaks during the active phase). Evening dosing may interfere with sleep in some individuals.

  • Administration form: Oral capsules are the most studied. Sublingual NMN claims faster absorption but lacks robust head-to-head pharmacokinetic comparison. Liposomal formulations claim enhanced bioavailability with limited human comparative data. Intranasal NAD+ sprays (used in some experimental gerotherapy trials) and IV NAD+ are alternative routes with thinner evidence bases.

  • Half-life and pharmacokinetics: Oral NR and NMN are rapidly absorbed and cleared (peaks within 30–60 minutes); whole-blood NAD+ elevation persists 8–24 hours. Niacin’s flushing reaction follows immediate-release peak within 15–30 minutes; extended-release reaches peak more gradually.

  • Single vs. split dosing: Most NR and NMN trials used single morning dosing, but the NR-VET trial (NCT04691986) and the original Martens NR pilot used split twice-daily dosing (500 mg morning + 500 mg evening). Niacin is typically split or extended-release for tolerability.

  • Genetic considerations: Variants affecting NAMPT, NRK1/2, and CD38 may affect precursor-to-NAD+ conversion. MTHFR and COMT (catechol-O-methyltransferase, an enzyme involved in methylation and neurotransmitter metabolism) variants may amplify the methylation-demand concern of high-dose nicotinamide. Pharmacogenomic testing is not standard but may inform individual choice.

  • Sex-based differences: No clinically significant sex-based differences in NAD+ precursor dosing have been established; most trials enrolled both sexes without reporting differential effects (the Yoshino NMN trial enrolled women only).

  • Age-related considerations: Adults over 60 may benefit from starting at the lower end of the dose range given potentially reduced kidney/liver clearance; the most robust trial data in older adults come from NR-Vet (NCT04691986) and the Kim and Morifuji NMN trials in adults aged 65+.

  • Baseline biomarker levels: Adults with documented low NAD+ (measurable via specialized whole-blood NAD+ assays such as Jinfiniti) may be candidates for higher initial doses. Routine NAD+ testing is not yet universally available.

  • Pre-existing health conditions: Adults with diabetes, prediabetes, dyslipidemia, or metabolic syndrome require closer glycemic and lipid monitoring, especially with niacin. Those with liver or kidney disease typically initiate supplementation only with physician oversight.

Discontinuation & Cycling

  • Long-term vs. short-term use: NAD+ supplementation is generally framed as a long-term intervention, since NAD+ decline is an ongoing aging process that resumes when supplementation stops. There is no established endpoint in healthy adults using NAD+ precursors for longevity purposes.

  • Withdrawal effects: No formal withdrawal effects are documented in clinical trials. NAD+ levels gradually return to pre-supplementation values over days to weeks rather than producing acute withdrawal. Some users (including Andrew Huberman) report a perceived energy decrement on discontinuation.

  • Tapering protocol: Tapering is not considered necessary based on current evidence; supplementation can be stopped abruptly without known adverse effects. Niacin dosing is the exception — for those on therapeutic niacin doses for lipid management, taper under medical supervision to avoid rebound effects.

  • Cycling: No established evidence supports cycling (e.g., 5 days on/2 off, 8 weeks on/4 off) as necessary for maintaining NAD+ supplementation efficacy. Some practitioner protocols incorporate periodic breaks based on the theoretical concern that chronic NAD+ elevation might downregulate endogenous NAMPT expression; this has not been demonstrated in humans. Most clinical trials used continuous daily dosing without cycling.

Sourcing and Quality

Source, purity, and formulation are critical for any NAD+-raising supplement, as the market has been plagued by quality issues. Independent testing has found that 29 of 39 NR products contained much less than labeled (many under 1%) and 14 of 22 popular Amazon-listed NMN products contained no detectable NMN at all. Conflict of interest note: A substantial portion of the NAD+ evidence base — including ingredient validation studies, brand-funded clinical trials, and trade-association marketing — is produced by parties with a direct financial interest in NAD+ supplementation’s adoption (ingredient suppliers such as ChromaDex/NIAGEN®, Uthever®/Effepharm; finished-product manufacturers; IV-clinic networks; and dietary-supplement industry advocacy groups). Brand and ingredient endorsements below should be read in that context.

  • Third-party testing: Choose products that provide independent, third-party certificates of analysis (COA) from reputable testing laboratories, verifying both purity (>99%) and potency (matching label claims).

  • GMP certification: Products manufactured in FDA-registered, GMP (Good Manufacturing Practice) certified facilities offer greater quality assurance than uncertified manufacturers.

  • Validated raw ingredients (NR): ChromaDex’s NIAGEN® is the most widely tested and clinically used NR ingredient; Tru Niagen, Life Extension NAD+ Cell Regenerator, and Thorne ResveraCel use NIAGEN®.

  • Validated raw ingredients (NMN): Uthever® NMN is the most widely tested and validated NMN ingredient and has been used in multiple clinical trials. MIB-626, a microcrystalline NMN polymorph (Pencina et al. 2023), is used in some research settings.

  • Niacin and nicotinamide: Pharmaceutical-grade niacin (Niaspan® extended-release) is FDA-approved for dyslipidemia; over-the-counter forms are widely available and inexpensive but vary in flushing intensity by formulation.

  • Stability and storage: NAD+ precursors (especially NMN, which is hygroscopic) can degrade at room temperature. Products should be stored in a cool, dry place; refrigeration may extend shelf life.

  • Reputable brands: ChromaDex/Tru Niagen, Life Extension NAD+ Cell Regenerator (NIAGEN®), Thorne, Pure Encapsulations, and ProHealth Longevity (Uthever® NMN) are commonly cited; ConsumerLab publishes a regularly updated list of top picks based on independent testing.

  • Forms available: Oral capsules (most studied), sublingual tablets/powder (potentially faster absorption, less validated), liposomal formulations (claimed enhanced bioavailability, limited comparative data), intranasal sprays (used in some longevity clinics and research protocols), and IV NAD+ (clinic-administered, limited rigorous data).

Practical Considerations

  • Time to effect: Whole-blood NAD+ rises within hours of the first dose; measurable elevation is consistently confirmed within 2 weeks. Subjective benefits (improved energy, sleep, exercise tolerance) are commonly reported within 2–6 weeks; clinical trial endpoints are generally measured at 6–12 weeks. Lipid-modifying effects of niacin appear within 4–8 weeks.

  • Common pitfalls: Purchasing low-quality or counterfeit NR/NMN products without third-party verification is the most consequential mistake; expecting dramatic, immediately noticeable longevity effects when these are typically subtle and cumulative; taking NAD+ precursors in the evening, which may disrupt sleep in sensitive individuals; using IV NAD+ outside controlled clinical settings; using high-dose nicotinamide as the chosen “NAD+ booster” when it does not actually raise NAD+ durably (Christen et al. 2026); neglecting baseline and follow-up labs; combining high-dose niacin with statins without monitoring CK.

  • Regulatory status: In the United States, NR is regulated as a New Dietary Ingredient (NDI) and is widely available. NMN’s regulatory status was clarified in 2025 when the FDA confirmed NMN is lawful for use in dietary supplements under the “race-to-market” provision. Niacin is available both over-the-counter and as the prescription drug Niaspan® (extended-release). Nicotinamide is a widely available vitamin. Intravenous NAD+ is administered under physician supervision; its compounded nature means it is not separately FDA-approved as a finished therapy.

  • Cost and accessibility: NAD+ precursors are moderately expensive. NR (NIAGEN®) at 300 mg/day from a reputable brand typically costs $40–$80/month; NMN at 250–500 mg/day costs $30–$80/month. Niacin is inexpensive ($5–$20/month at therapeutic doses). IV NAD+ infusions cost $300–$1,500 per session at longevity clinics, making this the most expensive route by a wide margin.

Interaction with Foundational Habits

  • Sleep: Direct, potentiating-or-blunting depending on timing. NAD+ precursors are involved in circadian regulation through SIRT1 (sirtuin 1, a NAD+-dependent enzyme regulating circadian rhythm), and several trials (Morifuji et al. 2024; Kim et al. 2022) have reported improved sleep quality. Conversely, evening dosing may disrupt sleep in sensitive individuals due to increased cellular energy metabolism. Practical consideration: take NAD+ precursors in the morning rather than evening.

  • Nutrition: Indirect, supportive. NAD+ precursors are present in small amounts in foods — niacin in meat and fortified grains, nicotinamide in dairy and meat, NMN in trace amounts in edamame, avocado, and broccoli. Dietary tryptophan (an essential amino acid that feeds the de novo NAD+ pathway) and adequate B-vitamins support overall NAD+ metabolism. Caloric restriction and time-restricted eating raise NAD+ endogenously through SIRT1/AMPK (AMP-activated protein kinase, a cellular energy sensor) activation. Practical consideration: take with food to improve gastrointestinal tolerability and, for niacin, to reduce flushing intensity.

  • Exercise: Direct, potentiating. Exercise — particularly endurance training — is one of the most reliable non-pharmacological ways to raise NAD+ and induce mitochondrial biogenesis. The RESTORENAD trial (NCT06425042) and the McDonald et al. (2025) acipimox study are testing whether NAD+ precursors potentiate exercise adaptations. There is no current evidence that NAD+ precursors blunt training adaptations — unlike high-dose antioxidant megadoses (vitamin C/E) which can impair certain training responses. Practical consideration: morning dosing fits well with most exercise schedules; the strongest evidence base for improved physical capacity comes from precursor-plus-exercise combinations.

  • Stress management: Indirect, supportive. NAD+ plays a role in the cellular stress response through SIRT1, sirtuin 3, and PARP activation. Chronic stress, infection, and inflammation increase PARP-driven NAD+ consumption, and supplementation could theoretically help maintain NAD+ pools under chronic stress. Direct effects on cortisol (the body’s primary stress hormone) have not been demonstrated in humans. Practical consideration: NAD+ precursors are not a substitute for stress-management practices and are best layered on top of them.

Monitoring Protocol & Defining Success

Baseline laboratory testing is performed in clinical practice before initiating NAD+ supplementation to establish reference values, screen for contraindications, and enable meaningful interpretation of subsequent measurements.

Ongoing monitoring follows a cadence of repeat testing at 3 months after starting, then every 6–12 months during continued supplementation. Adults over 60 or with pre-existing liver, kidney, metabolic, or cardiovascular conditions may benefit from more frequent monitoring (every 3 months). Niacin users at therapeutic doses warrant closer monitoring — every 6–12 weeks initially.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
NAD+ (whole blood, intracellular) >40 µM Directly measures the target molecule supplementation aims to raise Specialized test (e.g., Jinfiniti Diagnostics); not routinely available at standard labs. CMP (Comprehensive Metabolic Panel — a standard blood chemistry panel) does not measure NAD+. Fasting sample preferred.
Comprehensive Metabolic Panel Standard reference ranges Screens liver and kidney function, glucose, electrolytes for safety monitoring Includes liver enzymes, kidney function, glucose, electrolytes. Fasting for 8–12 hours required.
ALT 7–35 U/L (functional: <25 U/L) Monitors for liver stress, especially with niacin or high-dose nicotinamide ALT = alanine aminotransferase, a liver enzyme. Functional medicine practitioners prefer ALT <25 U/L; conventional upper limit is 35–40 U/L.
AST 10–35 U/L (functional: <25 U/L) Monitors for liver stress; elevated alongside ALT suggests hepatocellular injury AST = aspartate aminotransferase, a liver enzyme. Can also be elevated by intense exercise; time blood draw >48 hours after strenuous activity.
Creatinine / eGFR eGFR >90 mL/min/1.73m² Monitors kidney function eGFR = estimated glomerular filtration rate, a measure of kidney filtering capacity. Functional range is >90; conventional “normal” is >60.
Fasting glucose 72–85 mg/dL (functional) Tracks metabolic response, especially niacin-related glucose elevation Conventional normal is 70–99 mg/dL. Functional practitioners target 72–85 mg/dL. 8–12 hour fast required.
HbA1c 4.8–5.2% (functional) Longer-term glycemic monitoring, important for niacin users HbA1c = glycated hemoglobin, a marker of long-term blood sugar control. Conventional “normal” is <5.7%; functional optimal is <5.2%. No fasting required.
Lipid panel TC <200; LDL <100; HDL >60; TG <100 mg/dL Tracks lipid response, central for niacin and a relevant outcome for any NAD+ precursor TC = total cholesterol; LDL = low-density lipoprotein; HDL = high-density lipoprotein; TG = triglycerides. Fasting 12 hours recommended. Functional triglyceride target <100 vs. conventional <150 mg/dL.
hs-CRP <1.0 mg/L (functional) Tracks inflammatory response hs-CRP = high-sensitivity C-reactive protein, a marker of systemic inflammation. Conventional “normal” is <3.0 mg/L; functional optimal is <1.0 mg/L.
Uric acid 3.5–6.0 mg/dL Monitors for hyperuricemia, especially with niacin Niacin can raise uric acid and trigger gout. Important baseline if there is gout history.
CK (creatine kinase) <200 U/L Monitors muscle injury risk in those on niacin + statins CK = creatine kinase, a muscle injury marker. Significant elevations require evaluation for rhabdomyolysis.
Homocysteine 5–8 µmol/L Monitors methylation status with high-dose nicotinamide Homocysteine elevations may reflect methylation strain; relevant for high-dose nicotinamide users.

Qualitative markers to track:

  • Energy levels throughout the day (sustained vs. afternoon crashes)
  • Sleep quality (time to fall asleep, number of awakenings, feeling rested upon waking)
  • Cognitive clarity and focus
  • Exercise endurance and recovery time
  • Skin quality and appearance
  • Frequency and intensity of niacin flushing (if using niacin)
  • Overall sense of vitality and well-being

Emerging Research

Several active clinical trials and emerging research directions may significantly advance the understanding of NAD+ restoration over the next several years.

Conclusion

NAD+ is a fundamental cellular coenzyme required for energy metabolism, DNA repair, and the activity of longevity-associated enzymes. Its decline with age is well documented, and the rationale for restoring it is mechanistically robust. The most reliable finding from the human literature is that oral precursors — primarily nicotinamide riboside, nicotinamide mononucleotide, and niacin — durably raise circulating NAD+ within weeks, with niacin also producing well-established lipid-profile improvements.

Beyond that, the evidence becomes more uncertain. Promising signals exist for reduced inflammation, lower blood pressure, improved arterial stiffness, and modest sleep and physical-capacity gains in specific populations. Pooled meta-analyses, however, frequently return to the null on metabolic and muscular outcomes, and head-to-head comparative data between precursors and routes of administration remain limited.

Short-term safety appears reassuring for the oral precursors; niacin carries well-known flushing, hepatotoxicity, and glycemic considerations. Long-term human safety data are absent, and supplement-market quality control is poor enough that a meaningful fraction of products provide little or no labeled active ingredient.

For longevity-oriented adults already attending to sleep, nutrition, exercise, and stress, NAD+ restoration occupies a plausible but not conclusively proven position. Confidence is justified for raising the cofactor itself; modest support exists for inflammatory, vascular, and sleep benefits; uncertainty surrounds metabolic, muscular, and lifespan outcomes. A substantial share of supporting evidence comes from parties with a direct financial interest — ingredient suppliers, brands, infusion-clinic networks, and industry advocacy groups — tempering how independently strong the current case can be.

Top - Benefits - Risks - Protocol